Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 8/20 | 0.62 |
| ▸ | CTSS | P25774 | 1/20 | 0.59 |
| ▸ | CTSK | P43235 | 1/20 | 0.59 |
| ▸ | PSEN1 | P49768 | 6/20 | 0.55 |
| ▸ | PSEN2 | P49810 | 6/20 | 0.55 |
| ▸ | APH1B | Q8WW43 | 6/20 | 0.55 |
| ▸ | NCSTN | Q92542 | 6/20 | 0.55 |
| ▸ | APH1A | Q96BI3 | 6/20 | 0.55 |
| ▸ | PSENEN | Q9NZ42 | 6/20 | 0.55 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.55 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.55 |
| ▸ | CTSD | P07339 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30485406 | 1.00 | REN (0.62) | RENCTSSCTSKPSEN1PSEN2 | |
| SCHEMBL28377172 | 1.00 | REN (0.62) | RENCTSSCTSKPSEN1PSEN2 | |
| SCHEMBL28373438 | 1.00 | REN (0.62) | RENCTSSCTSKPSEN1PSEN2 | |
| SCHEMBL84538 | 1.00 | REN (0.62) | RENCTSSCTSKPSEN1PSEN2 | |
| SCHEMBL28372334 | 1.00 | REN (0.62) | RENCTSSCTSKPSEN1PSEN2 | |
| SCHEMBL30485379 | 1.00 | REN (0.62) | RENCTSSCTSKPSEN1PSEN2 | |
| SCHEMBL28372331 | 1.00 | REN (0.62) | RENCTSSCTSKPSEN1PSEN2 | |
| SCHEMBL17452195 | 0.94 | CTSS (0.63) | RENCTSSCTSKPSEN1PSEN2 | |
| SCHEMBL8073093 | 0.94 | REN (0.68) | RENCTSSCTSKPSEN1PSEN2 | |
| SCHEMBL18171935 | 0.94 | REN (0.68) | RENCTSSCTSKPSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180298056-A1 | PROCESS FOR THE PREPARATION OF (2S)-N-((S)-1-((S)-4-METHYL-1-((R)-2-METHYL OXIRAN-2-YL)-1-OXOPENTAN-2-YLCARBAMOYL)-2-PHENYLETHYL)-2-((S)-2-(2-MORPHOLINO ACETAMIDO)-4-PHENYLBUTANAMIDO)-4-METHYLPENTANAMIDE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2018-10-18 | — | — | US | claimed |
| WO-2016170544-A1 | PROCESS FOR THE PREPARATION OF (2S)-N-((S)-1-((S)-4-METHYL-1-((R)-2-METHYL OXIRAN-2-YL)-1-OXOPENTAN-2-YLCARBAMOYL)-2-PHENYLETHYL)-2-((S)-2-(2-MORPHOLINO ACETAMIDO)-4-PHENYLBUTANAMIDO)-4-METHYLPENTANAMIDE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2016-10-27 | — | — | WO | claimed |
| US-10544189-B2 | Process for the preparation of (2S)-N-((S)-1-((S)-4-methyl-1-((R)-2-methyl oxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)-4-methylpentanamide | MSN LABORATORIES PRIVATE LIMITED (IN) | 2020-01-28 | — | — | US | disclosed |
| US-10329325-B2 | Process for the preparation of (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxo-pentan-2-yl) amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido) pentanamide | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD (IN) | 2019-06-25 | — | — | US | disclosed |
| US-20180298056-A1 | PROCESS FOR THE PREPARATION OF (2S)-N-((S)-1-((S)-4-METHYL-1-((R)-2-METHYL OXIRAN-2-YL)-1-OXOPENTAN-2-YLCARBAMOYL)-2-PHENYLETHYL)-2-((S)-2-(2-MORPHOLINO ACETAMIDO)-4-PHENYLBUTANAMIDO)-4-METHYLPENTANAMIDE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2018-10-18 | — | — | US | disclosed |
| US-20170298093-A1 | Process for the Preparation of (S)-4-Methyl-N-((S)-1-(((S)-4-Methyl-1-((R)-2-Methyloxiran-2-YL)-1-OXO Pentan-2-YL) Amino)-1-OXO-3-Phenylpropan-2-YL)-2-((S)-2-(2-Morpholinoacetamido)-4-Phenylbutanamido) Pentanamide | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD (IN) | 2017-10-19 | — | — | US | disclosed |
| WO-2016185450-A1 | AN IMPROVED PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS PRIVATE LIMITED (IN) | 2016-11-24 | — | — | WO | disclosed |
| WO-2016170544-A1 | PROCESS FOR THE PREPARATION OF (2S)-N-((S)-1-((S)-4-METHYL-1-((R)-2-METHYL OXIRAN-2-YL)-1-OXOPENTAN-2-YLCARBAMOYL)-2-PHENYLETHYL)-2-((S)-2-(2-MORPHOLINO ACETAMIDO)-4-PHENYLBUTANAMIDO)-4-METHYLPENTANAMIDE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2016-10-27 | — | — | WO | disclosed |
| WO-2009045497-A1 | CRYSTALLINE PEPTIDE EPOXY KETONE PROTEASE INHIBITORS AND THE SYNTHESIS OF AMINO ACID KETO-EPOXIDES | PROTEOLIX, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544189-B2 | Process for the preparation of (2S)-N-((S)-1-((S)-4-methyl-1-((R)-2-methyl oxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)-4-methylpentanamide | OPRL1, PNMT, HTR1A | REN 853/4885CTSS 3195/4885CTSK 4479/4885 |
| US-20170298093-A1 | Process for the Preparation of (S)-4-Methyl-N-((S)-1-(((S)-4-Methyl-1-((R)-2-Methyloxiran-2-YL)-1-OXO Pentan-2-YL) Amino)-1-OXO-3-Phenylpropan-2-YL)-2-((S)-2-(2-Morpholinoacetamido)-4-Phenylbutanamido) Pentanamide | PSMA1, PSMA2, PSMA6 | REN 139/4885CTSS 68/4885CTSK 365/4885 |
| US-20180298056-A1 | PROCESS FOR THE PREPARATION OF (2S)-N-((S)-1-((S)-4-METHYL-1-((R)-2-METHYL OXIRAN-2-YL)-1-OXOPENTAN-2-YLCARBAMOYL)-2-PHENYLETHYL)-2-((S)-2-(2-MORPHOLINO ACETAMIDO)-4-PHENYLBUTANAMIDO)-4-METHYLPENTANAMIDE | OPRL1, OPRM1, ADRA1D | REN 734/4885CTSS 3324/4885CTSK 4506/4885 |
| US-10329325-B2 | Process for the preparation of (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxo-pentan-2-yl) amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido) pentanamide | PSMA1, PSMA2, PSMA3 | REN 129/4885CTSS 108/4885CTSK 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.